Evidence map›Paper›PMID 34058261›Full record

ArticleThe Journal of infection2021

Persistence of humoral immune response to SARS-CoV-2 up to 7 months post-infection: Cross-sectional study, South India, 2020-21.

Jeromie Wesley Vivian Thangaraj, Muthusamy Santhosh Kumar, Cp Girish Kumar, V Saravana Kumar, Nathella Pavan Kumar, Tarun Bhatnagar, Manickam Ponnaiah, R Sabarinathan, D Sudharani, Arul Nancy and 3 more

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infection, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Jeromie Wesley Vivian ThangarajICMR National Institute of Epidemiology, Chennai, India.
Muthusamy Santhosh KumarICMR National Institute of Epidemiology, Chennai, India.
Cp Girish KumarICMR National Institute of Epidemiology, Chennai, India.
V Saravana KumarICMR National Institute of Epidemiology, Chennai, India.
Nathella Pavan KumarICMR National Institute of Epidemiology, Chennai, India.
Tarun BhatnagarICMR National Institute of Epidemiology, Chennai, India.
Manickam PonnaiahICMR National Institute of Epidemiology, Chennai, India.
R SabarinathanICMR National Institute of Epidemiology, Chennai, India.
D SudharaniICMR National Institute of Epidemiology, Chennai, India.
Arul NancyICER-ICMR-NIRT-International Center for Excellence in Research, Chennai, India.
M JagadeesanGreater Chennai Corporation, Chennai, India.
Subash BabuICER-ICMR-NIRT-International Center for Excellence in Research, Chennai, India.
Manoj MurhekarICMR National Institute of Epidemiology, Chennai, India. Electronic address: mmurhekar@nieicmr.org.in.

Funding

India International Center for Excellence in ResearchZIAAI001065 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI NUTMAN, THOMAS · 2009 to 2025
$19.0M
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19SARS-CoV-2Antibodies, ViralCross-Sectional StudiesHumansImmunity, HumoralAntibodies, Viral

Identifiers

PMID34058261
PMCPMC8160281

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.